Schlieren, Switzerland – October 16, 2019 – AL-S Pharma AG, a biotech company jointly founded and financed by Neurimmune and TVM Capital Life Science, announced today enrollment of the first patient …
News
Lilly’s REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval
The approval of REYVOW is significant because it represents the first new class of acute migraine treatment approved by the FDA in more than two decades INDIANAPOLIS, Oct. 11, 2019 /PRNewswire/ -- …
Emovi Announces Results of Clinical Trial to Manage Knee Osteoarthritis with KneeKGTM
Results demonstrates that use of KneeKG in patients with osteoarthritis reduces pain, improves patient quality of life, and may reduce need for unnecessary surgery. Montreal, Quebec (October 1st, …
Proteon Therapeutics and ArTara Therapeutics Agree to Combine
September 23, 2019 Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company Focused on Immunology and Metabolic Disorders $42.5M Concurrent Financing to be Led by a …
BIO Deutschland – Biotechnologie-Branchenverband wählt Dr Hubert Birner in den Vorstand
Berlin (17. September 2019) – Der Branchenverband der Biotechnologie-Industrie, BIO Deutschland e. V., hat gestern während der 16. ordentlichen Mitgliederversammlung in Berlin einen neuen Vorstand für …
We are very proud to have won the Deal of The Year Award 2019!
The Canadian Venture Capital and Private Equity Association (CVCA) announced the winners of its annual Deal of the Year awards during its annual Invest Canada 19 conference taking place in …